PR Newswire (Fri, 7:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,517 people get MYL articles and Market Currents by email alert.
Get email alerts on MYL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
PR Newswire (Wed, 11:40AM)
-
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
-
PR Newswire (Apr 22, 2013)
-
-
-
PR Newswire (Apr 9, 2013)
-
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 13, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
Why You Should Hold On To MylanDieter Plas • Thu, Feb 7 -
Obamacare Just Part Of The Mylan StoryDana Blankenhorn • Fri, Nov 9, 2012 -
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012 -
Generics Will Drive Mylan Higher By 2013Cris Frangold • Fri, Aug 31, 2012
-
-
Mylan: Execution, Valuation Discount Suggest Further Upside AheadAlex Shadunsky • Tue, May 22, 2012 -
-
-
-
-
Mylan: Earnings PreviewZacks Investment Research • Mon, Jul 25, 2011 -
-
Mylan: Earnings PreviewZacks Investment Research • Wed, Apr 27, 2011
-
Diagonal Spread in Mylan Has Bearish BiasoptionMONSTER • Tue, Mar 23, 2010 -
Mylan Strengthens Portfolio With Generic Diabetes DrugsZacks Investment Research • Wed, Mar 17, 2010
-
Earnings Preview: MylanTheflyonthewall • Wed, Oct 28, 2009 -
Earnings Preview: MylanTheflyonthewall • Wed, Jul 29, 2009
-
Mylan: Showing Up DoubtersAllen Phatimer • Mon, Feb 23, 2009
-
-
-
-
-
-
-
-
Billionaire John Paulson's Top Stock PicksInsider Monkey • Thu, Feb 21
-
-
-
-
-
-
-
-
-
-
-
-
VIX - Options Volatility Sonar: Friday RecapErick McKitterick • Fri, Oct 26, 2012
-
Mylan Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Mylan Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Mylan's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Mylan, Inc. - Analyst/Investor DayTue, Feb 21, 2012
-
Mylan's CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Oct 26, 2011
-
Mylan's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Jul 27, 2011
-
Mylan's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 24, 2011
-
Mylan Q3 2010 Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan Laboratories Inc. Q1 2010 Earnings Call TranscriptThu, Apr 29, 2010
-
Mylan Inc. Q4 2009 Earnings Call TranscriptMon, Mar 1, 2010
-
Mylan Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
Mylan Inc. Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
Mylan Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Mylan Inc Q2 2008 Earnings Call TranscriptWed, Aug 6, 2008
-
Mylan Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
PR Newswire (Fri, 7:30AM)
-
at CNBC.com (Thu, 7:33AM)
-
PR Newswire (Wed, 11:40AM)
-
at CNBC.com (Wed, 7:42AM)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
at CNBC.com (Apr 26, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 3, 2013)
-
at CNBC.com (Mar 25, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 4, 2013)
-
at MarketWatch.com (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 23, 2013)
MYL vs. ETF Alternatives
Company Description
Long considered a leader in the United States (“U.S.”) generic pharmaceutical market, Mylan has grown into a worldwide pharmaceutical leader and is currently the third largest generic and specialty pharmaceutical company in the world, in terms of revenues. This evolution has taken place through... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 17, 2:34 PM Actavis' (ACT +1.5%) pursuit of Warner Chilcott (WCRX +0.5%) may be a way to defend itself from a potential takeovers by Valeant Pharmaceuticals (VRX +2.5%) and Mylan (MYL +2.2%). VRX routinely looks at potential acquisitions, but to date has stayed away from WCRX because of its dwindling pipeline, so a combined ACT/WCRX deal would be out of the picture. And it would be virtually impossible for MYL, with a market value of $11.7B, to buy the combined firm. It already has about $6B in debt and Street estimates put a combined companies near $21B. Comment! [Healthcare, M&A]
- Wednesday, May 15, 8:28 PM Actavis (ACT), which has rebuffed overtures from both Valeant (VRX) and more recently Mylan (MYL), may soon receive a bid from Novartis (NVS), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling a consolidation scramble in the generic-drug industry, the Journal notes, and ACT — which is also playing the role of acquirer in negotiations with Warner Chilcott (WCRX) — is at the center of the deal-making rumor mill. Comment! [Healthcare]
- Wednesday, May 15, 12:14 PM Mylan (MYL +0.4%) receives final approval from the FDA for its Abbreviated New Drug Application for Zolmitriptan Tablets, a generic version of IPR Pharmaceuticals migraine treatment Zomig. Zolmitriptan had U.S. sales of approximately $152.8M for the 12 months ending March 31. MYL has already begun shipping. Comment! [Healthcare]
- Tuesday, May 14, 1:29 PM Actavis (ACT +1.2%) spikes on reports that the company recently turned away a $15B bid from Mylan (MYL +0.1%). Comment! [Healthcare, On the Move, M&A]
- Thursday, May 2, 5:18 PM More on Mylan (MYL): Q1 misses on top line estimates as net earnings fell 17% Y/Y amid acquisition-related expenses and other items. The generic-drug maker reported modest growth for the quarter, thanks to its specialty business which posted revenue growth of 22% to $226.6M. Generics revenue was flat at $1.41B, as growth in its EMEA segment and its Asia Pacific business was offset by declines in North America. Gross margin rose slightly to 42.5% from 42.3%. Shares -3.4% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, May 2, 4:34 PM Mylan Labs (MYL): Q1 EPS of $0.62 in-line. Revenue of $1.63B misses by $0.07B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 2, 12:10 AM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
- Wednesday, May 1, 5:35 PM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
- Tuesday, April 30, 1:44 PM The FDA approves Raptor Pharmaceuticals' (RPTP +11%) Procysbi, a delayed-release version of Mylan's (MYL -0.1%) Cystagon. The drugs treat nephropathic cystinosis. RPTP could see revenues of $77M in 2015 from the drug, Bloomberg says. Comment! [Healthcare, On the Move]
- Friday, April 5, 6:19 PM J.P. Morgan's Thomas Lee notes that several laggards in the first quarters of 2009-12 rebounded in Q2, so he figures select tech stocks look appealing now. Tech's forward P/E ratio is below the market's for the first time in 17 years, Lee says. His most noteworthy call is to buy Apple (AAPL), which slid 16% Q/Q. Some other favorites: BRCM, CHKP, ESRX, MYL, TASR, CHS, F, COF. 14 Comments [Tech, Quick Ideas]
- Thursday, April 4, 8:38 AM Mylan's (MYL) success in obtaining approval for a generic version of Valeant's (VRX) Zovirax herpes ointment will hit the latter's cash EPS by $0.30-0.40 in 2013. Valeant says that product acquisitions, the repricing of its term loan debt, and other factors will help mitigate the impact of the genericization of Zovirax. VRX is +1.5% after slumping 4.6% yesterday. (PR) Comment! [Healthcare]
- Wednesday, April 3, 5:25 PM Mylan (MYL), which traded markedly lower for most of the session Wednesday, retraced most of its losses to close nearly flat after announcing it has received final FDA approval to ship the first generic version of Valeant's (VRX) Zovirax Ointment. Shares of VRX moved sharply lower after the announcement. Comment! [Healthcare]
- Wednesday, March 13, 4:02 PM Mylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with Shionogi and Andrx to resolve patent litigation related to the generic version of Shionogi's Fortamet, an adjunct to diet and exercise to lower blood glucose. The terms of the settlement agreement are confidential, but has been disclosed it that MYL may launch a generic version of Fortamet on August 1, 2013, or earlier under certain conditions. Comment! [Healthcare, Global & FX]
- Wednesday, February 27, 5:18 PM Mylan (MYL) acquires Agila Specialties, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab for $1.6B in cash. The acquisition significantly expands MYL's global injectables platform and will provide entry into new high-growth geographic markets. The acquisition is expected to close in Q4 of 2013 should be immediately accretive to earnings. Shares +1.8% AH. 1 Comment [Healthcare, M&A, On the Move]
- Wednesday, February 27, 5:02 PM Mylan Labs (MYL): Q4 EPS of $0.65 beats by $0.02. Revenue of $1.72B (+13% Y/Y) misses by $0.01B. Shares -2% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Wednesday, February 27, 12:10 AM Notable earnings after Wednesday’s close: AGO, AHT, ANW, ARI, CBI, CDXS, CECO, CLR, DAR, DPM, DVR, GRPN, HNSN, IOC, ITC, JCP, LTD, MBI, MMLP, MNST, MWE, MYL, PANL, PLL, RGR, UAN, WES, WLL Comment! [Earnings]
-
- View all 0 replies
-
StockViews
Canaccord downgrade $MYL to HOLD. "Catalysts behind us and upside limited". View 2013 as a "transition year" - View all 0 replies
-
Jim Van Meerten
$MYL - 100% Barchart technical buy signals - 8 new highs and up 5.25% in the last month - Relative Strength Index 65.70% - View all 0 replies
-
Jim Van Meerten
$MYL - 96% Barchart technical buy signal - 9 new hgihs and up 6.94% in the last month - Relative Strength Index 67.89% - View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 6 new highs and up 4.48% in the last month - Relative Strength Index 63.0% - View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 5 new highs and up 2.89% in the last month - Relative Strength Index 63.03% - View all 0 replies
-
- View all 0 replies
-
John Motyka
I sold MYL prematurely in light of this weeks' action. I continue to Hold my position in MAKO...JDM - View all 0 replies
-
John Motyka
IMUC and LGND moving against down market. Both feature similar paradigm shifting healthcare treatment modalities. Sold MYL for LT gain. - View all 0 replies
LATEST REPLIES